Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported ($1.64) EPS for the quarter, missing the consensus estimate of $1.37 by ($3.01), Zacks reports. The firm had revenue of $42.81 million during the quarter, compared to the consensus estimate of $39.03 million. Ligand Pharmaceuticals had a return on equity of 4.95% and a net margin of 29.68%. Ligand Pharmaceuticals updated its FY 2025 guidance to 6.000-6.250 EPS.
Ligand Pharmaceuticals Stock Down 8.2 %
Shares of NASDAQ:LGND traded down $10.05 during trading on Monday, reaching $112.18. 164,247 shares of the company traded hands, compared to its average volume of 94,481. Ligand Pharmaceuticals has a 52 week low of $67.72 and a 52 week high of $129.90. The firm has a market capitalization of $2.12 billion, a PE ratio of 44.69 and a beta of 1.04. The company's 50 day moving average is $114.18 and its two-hundred day moving average is $111.29.
Insider Buying and Selling
In related news, CFO Octavio Espinoza sold 2,104 shares of the company's stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $116.37, for a total transaction of $244,842.48. Following the completion of the sale, the chief financial officer now directly owns 20,647 shares in the company, valued at $2,402,691.39. This represents a 9.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.90% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on LGND shares. Oppenheimer lifted their price objective on Ligand Pharmaceuticals from $135.00 to $147.00 and gave the company an "outperform" rating in a report on Friday, November 8th. Royal Bank of Canada raised their target price on Ligand Pharmaceuticals from $141.00 to $143.00 and gave the stock an "outperform" rating in a report on Wednesday, December 11th. Barclays boosted their target price on Ligand Pharmaceuticals from $150.00 to $160.00 and gave the company an "overweight" rating in a research note on Monday, December 16th. HC Wainwright reaffirmed a "buy" rating on shares of Ligand Pharmaceuticals in a research report on Wednesday, December 11th. Finally, Benchmark reaffirmed a "buy" rating and set a $135.00 price target on shares of Ligand Pharmaceuticals in a research report on Monday, December 23rd. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Ligand Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $147.00.
Read Our Latest Stock Report on LGND
Ligand Pharmaceuticals Company Profile
(
Get Free Report)
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
See Also

Before you consider Ligand Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ligand Pharmaceuticals wasn't on the list.
While Ligand Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.